Trial Profile
CAR-T Cell Therapy for Relapsed / Refractory CD19 Positive Clinical Study on the Safety and Effectiveness of Lymphoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-CD19-chimeric-antigen-receptor-T-cell-therapy-Sinobioway-Cell-Therapy (Primary)
- Indications B-cell lymphoma
- Focus Therapeutic Use
- Sponsors Sinobioway Cell Therapy
- 06 Apr 2018 New trial record